

Fertilite Koruyucu Laparoskopik Cerrahi

- Over Transpozisyonu
- Over Dokusu
İmplantasyonu

Dr. L. Cem Demirel

Memorial Ataşehir IVF

Strategies for fertility preservation

1. Reducing toxicity
2. Cryopreservation
3. Conservative surgery



Fertility sparing surgery

1. Ovarian cancer :

- Borderline tumours
- Invasive carcinoma stage Ia G1

2. Endometrial cancer: stage Ia G1,

3. Cervical cancer: < 2 cms, stages Ia - Ib1,


Querleu D et al, Bull Cancer 2008

Gurgan T et al, Placenta 2008

Fujiwara H et al, Hum Rep 2009

Koskas et al. Fertil Steril 2012

% Survival in Common Pediatric Cancers



ASSESSMENT OF RISK OF SUBFERTILITY AFTER TREATMENT FOR COMMON CANCERS IN CHILDHOOD AND ADOLESCENCE

Low risk <20%	Acute lymphoblastic leukemia Wilm's tumor Soft-tissue sarcoma: stage I Germ-cell tumors (with gonadal preservation and no radiotherapy) Retinoblastoma Brain tumor: surgery only, cranial irradiation <24 Gy
Medium risk	Acute myeloblastic leukemia Hepatoblastoma Osteosarcoma Ewing's sarcoma stage II or III Neuroblastoma Non-Hodgkin lymphoma Hodgkin's disease: alternating treatment Brain tumor: craniospinal radiotherapy, cranial irradiation >24 Gy
High risk >80%	Whole-body irradiation Localized pelvic radiotherapy Chemotherapy conditioning for bone-marrow transplantation Hodgkin's disease: treatment with alkylating drugs Soft-tissue sarcoma: stage IV Metastatic Ewing's sarcoma

NON-MALIGNANT PATHOLOGIES WITH RISK OF POF

Bone-marrow transplantation

Sickle cell anemia

Thalassemia major

Aplastic anemia

Autoimmune diseases unresponsive to immunosuppressive therapy

Autoimmune diseases requiring chemotherapy

Systemic lupus erythematosus

Rheumatoid arthritis

Behcet's disease

Wegener's disease

Multiple sclerosis

Ovarian pathologies

Recurrent ovarian cysts

Ovarian torsion

Endocrine or genetic diseases

Turner syndrome


Galactosemia

Family history of premature ovarian failure

Sex reassignment surgery in transsexuals

Modified from P. JADOUL et al (2010)

Human Reproduction Update 16-6, 617-630



Fertility Preservation in Cancer Patients

1st choice

OOCYTE CRYOPRESERVATION

- Women willing to conceive
- Oncologist consultation and approval
- Does not exclude ovarian cortex removal

Concerns:

- Cross-contamination

OVARIAN CORTEX CRYOPRESERVATION

- Girls
- Contraindication for ovarian stimulation
- Oncologist disapprove stimulation
- No time for ovarian stimulation

Concerns:

- Leukaemia
- Cross-contamination

The risk of ovarian metastasis according to cancer types

Cancers with low risk of ovarian involvement

Wilm's tumour

Ewing's sarcoma

Breast cancer

Stage I-III

Infiltrative ductal histological subtype

Non-Hodgkin's lymphoma

Hodgkin's lymphoma

Non-genital rhabdomyosarcoma

Osteogenic sarcoma

Squamous cell carcinoma of the cervix

Cancers with moderate risk of ovarian involvement

Adenocarcinoma/adenosquamous carcinoma of the cervix

Colon cancer

Breast cancer

Stage IV

Infiltrative lobular histological subtype

Cancers with high risk of ovarian involvement

Leukaemia

Neuroblastoma

Burkitt lymphoma

AUTOTRANSPLANTATION OF CRYOPRESERVED OVARIAN TISSUE IN CANCER SURVIVORS AND THE RISK OF REINTRODUCING MALIGNANCY: A SYSTEMATIC REVIEW

L. Bastings et al.

Methods: A systematic review of literature

Results: A total of 289 studies were included

Conclusions: It is advisable to refrain from ovarian tissue autotransplantation in survivors of leukaemia. With survivors of all other malignancies, current knowledge regarding the safety of autotransplantation should be discussed. The most reassuring data regarding autotransplantation safety were found for lymphoma patients.

CRYOPRESERVATION	CHARACTERISTICS
Embryos	<p data-bbox="1058 568 1566 639">9.5 ± 2.33 days</p> <p data-bbox="1199 701 1406 739">HUQD, 2013</p>
Oocytes	
Ovarian tissue	<p data-bbox="817 893 1508 932">Minimum a surgical intervention</p> <p data-bbox="817 993 1711 1079">No need for ovarian stimulation . No time limitation</p> <p data-bbox="817 1142 1789 1228">Risk of reimplanting malignant cells (minimal in breast cancer)</p> <p data-bbox="817 1290 1128 1329">Graft survival?</p>

LONG-TERM DURATION OF FUNCTION OF OVARIAN TISSUE TRANSPLANTS: CASE REPORTS

Claus Y. Andersen et al

These **three** case reports describe the long-term duration of function of ovarian cortical tissue grafts among patients in a university fertility preservation programme in Europe and in a private practice programme in the USA. One woman underwent sterilizing cancer treatment and had frozen ovarian tissue transplanted, and two women underwent fresh ovarian tissue transplants. The function of ovarian cortical strips has continued for more than **7** years in these three women, with the birth of eight healthy babies following a single graft per patient.

Cryopreservation of ovarian tissue: 3 options

Cortical ovarian biopsy

Whole ovary

Fragments

Isolated follicles



Isolation

Avascular transplantation

In vitro culture

Avascular transplantation

Vascular transplantation

Orthotopic

Heterotopic

30 Livebirths

AVOIDS TRANSMISSION OF MALIGNANT CELLS



AVOIDS FOLLICULAR LOSS DUE TO ISCHEMIA

Xenograft

LS excision of ovarian tissue for cryo



Reimplantasyon - I



Reimplantasyon - II





Overin medullasına suture edilmiş dondurulmuş over dokusu parçaları



İskemi

- Primordial follüküllerin çođu transplantasyon sonrası kaybedilir (survi:%5-50)
- Teorik olarak:antioksidan veya anti apopitotik kullanımı veya anjiogenez indüksiyonu (GT kullanımı)
- Anjiogenez 48 saat-7gün




TABLE 1


Follicular viability before and after freeze-thawing.

Variable	Follicles in fresh ovary (n = 312)	Follicles in fresh ovary after DMSO exposure (n = 153)	Follicles in frozen-thawed ovary (n = 356)
% Live follicles	99.4 ± 1.0 ^a	98.1 ± 3.2 ^a	75.1 ± 1.9 ^b
% Minimally damaged follicles	0.6 ± 1.0 ^a	1.9 ± 3.2 ^a	22.5 ± 2.2 ^b
% Moderately damaged follicles	0 ± 0 ^a	0 ± 0 ^a	2.4 ± 1.1 ^b
% Dead follicles	0 ± 0 ^a	0 ± 0 ^a	0 ± 0 ^a

^{ab} Within each row, values (mean ± SEM) with differing superscripts are significantly different ($P < .05$).

Martinez-Madrid. Freezing intact human ovary. Fertil Steril 2004.

Frozen vs Fresh ortotopik reimplantasyon





Reimplantasyondan 4.5 ay sonra 14 mm lik folikül

Bir hafta sonra 21 mm lik korpus luteum ve eşlik eden 6.5 ng / mL P₄ değeri

Gonadotoxic effect Radiotherapy

- **Dose received:** in humans dose reducing follicular population to half is 2 Gy
- **Age**
- **Irradiation field:** probability of POF increases if corporal irradiation
- May have effects on **other structures**

RT doses and ovarian toxicity, according to age

Dose	Effect
60	no
60-150	>40: possible
250-500	15-40: 50% sterile
500-800	15-40: 75% sterile
>800	100% sterile

Wallace, 2005

Malign hastalıklarda ovarian transpozisyon endikasyonları

Jinekolojik maligniteler

- Erken servikal karsinom
- Erken vajinal karsinom
- Erken vulvar karsinom

Non-jinekolojik maligniteler

- Rektosigmoid tümör
- Pelvik ya da extrapelvik sarkoma
- Kemik kanseri (osteosarkoma, Ewing sarkomu)
- Lenfoma
- Medulloblastoma

Ovarian Transposition (Oophoropexia)

Objective:

Move ovaries away from irradiation field to avoid direct exposition to radiotherapy

- Laparoscopy or laparotomy
- They can be fixed in the upper paracolic gutters or behind uterus
- Gonadal protection in 60% of the cases
- Ovarian function preservation in 83-88% of the cases
- Complications: vascular lesions, Fallopian tube infarct, cyst formation

Ovarian transposition

Objective:

To move the ovaries from the irradiation field before starting RT

Indication:

Tumours requiring pelvic irradiation



Technique:


Laparoscopic / laparotomic



Important:

- Preserving ovarian vascularization
- Easy access for possible future OPU
- Cryopreserving ovarian fragments







Tulandi et al, Obstet Gynecol Clin N Am , 2004





Teşekkür ederim.....